Emergent Biosolutions, Inc. (NYSE:EBS) EVP Adam Havey sold 7,885 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $37.06, for a total transaction of $292,218.10. Following the completion of the sale, the executive vice president now owns 33,931 shares of the company’s stock, valued at $1,257,482.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Emergent Biosolutions, Inc. (NYSE:EBS) opened at 38.10 on Friday. Emergent Biosolutions, Inc. has a 12-month low of $24.47 and a 12-month high of $38.74. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of 24.26 and a beta of 1.23. The company’s 50-day moving average is $36.14 and its 200-day moving average is $32.54.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.13). The company had revenue of $100.77 million during the quarter, compared to the consensus estimate of $111.57 million. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.05) earnings per share. Analysts predict that Emergent Biosolutions, Inc. will post $1.54 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Emergent Biosolutions, Inc. (EBS) EVP Sells $292,218.10 in Stock” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/09/15/insider-selling-emergent-biosolutions-inc-ebs-evp-sells-292218-10-in-stock.html.

EBS has been the subject of a number of recent research reports. Zacks Investment Research lowered shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Monday, July 17th. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $44.00.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Emergent Biosolutions by 6.7% in the first quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock worth $109,574,000 after buying an additional 238,194 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Emergent Biosolutions by 7.4% in the second quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock worth $74,795,000 after buying an additional 152,029 shares during the last quarter. Aberdeen Asset Management PLC UK lifted its position in Emergent Biosolutions by 7.3% in the second quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock worth $58,918,000 after buying an additional 118,894 shares during the last quarter. State Street Corp lifted its position in Emergent Biosolutions by 17.2% in the first quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock worth $42,180,000 after buying an additional 213,500 shares during the last quarter. Finally, Snyder Capital Management L P lifted its position in Emergent Biosolutions by 17.8% in the first quarter. Snyder Capital Management L P now owns 1,134,332 shares of the biopharmaceutical company’s stock worth $32,941,000 after buying an additional 171,636 shares during the last quarter. Institutional investors own 85.44% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.